These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27878277)

  • 1. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
    Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
    Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
    Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
    Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide reverses the resistance of A2780/Pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitro.
    Shen Y; Zhang XY; Chen X; Ren ML; Cai YL
    J Cancer Res Ther; 2016; 12(2):657-62. PubMed ID: 27461627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
    Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
    Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 8. [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].
    Xiao L; Gao R; Lu S; Lu MS; Liang ML; Ren LR; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):412-6. PubMed ID: 17697605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
    Sun NK; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
    Huang CZ; Wang YF; Zhang Y; Peng YM; Liu YX; Ma F; Jiang JH; Wang QD
    Oncol Rep; 2017 Oct; 38(4):2558-2564. PubMed ID: 28791369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
    Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
    Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.
    Liu Y; Xia H; Wang Y; Han W; Qin J; Gao W; Qu X; Wang X
    Thorac Cancer; 2021 Nov; 12(22):3053-3061. PubMed ID: 34617400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].
    Li ZM; Hu S; Xiao L; Wang J; Cai J; Yu LL; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):372-5. PubMed ID: 20646448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
    Li Y; Sun J; Gao S; Hu H; Xie P
    Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
    Xu Y; Zhang J; Wu J; Zhong S; Li H
    Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
    Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
    Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.